Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Lab study finds dying cancer cells switch off the immune attack, a clue for immunotherapy

☕ Includes a question for the family ↓

How immunotherapy worksPart of a story we are following · 6 articles · See every update
A group of hikers walks through a wildflower meadow with forested mountains in the background.
A group of hikers walks through a wildflower meadow with forested mountains in the background.Photo: Patrick Piemonte / Wikimedia Commons, CC BY-SA 3.0

Here is some new research on cancer. Scientists have worked out how dying cancer cells hide from the immune system, and they found a way to stop the hiding. This is early lab work and has not been tested in people yet.

In lab studies of cancer cells, researchers found that cells being destroyed by a treatment trigger called ferroptosis release a chemical signal, PGE2, that switches off the immune attack. When the team blocked that signal, the immune system went back to work and tumors were eliminated. The authors say this finding could be exploited for cancer therapy.

How the study worked

This was preclinical research, meaning it was done in the lab and not in patients. The team studied cancer cells and the immune cells that respond to them, and published the results in Nature on November 18, 2026. The next step is to see whether the same thing holds up in people.

What is ferroptosis?

Ferroptosis is a way a cell can die. The fatty outer wall of the cell gets damaged by a kind of chemical rust, and the cell falls apart. Many cancers are weak to this kind of death, including some cancers that do not respond to current drugs and immune-based treatments. That makes ferroptosis an attractive tool.

There was a catch. Earlier work had shown that the immune system has to join in for this approach to clear a tumor fully. Yet the dying cancer cells somehow held that immune response back. Until now, nobody knew how.

What they found

The researchers found the hidden step. Think of the immune system as a team with scouts and fighters. The scouts are called type 1 conventional dendritic cells. The fighters are CD8+ T cells. The scouts show the fighters what to attack.

When cancer cells die by ferroptosis, their damaged outer wall lets calcium flood in. That wakes up an internal switch called p38 MAPK, and the cell starts making a chemical called prostaglandin E2, or PGE2. The PGE2 then weakens the scouts, so the fighters never get a strong call to action. The tumor escapes.

Here is the good part. This switch works separately from the cell’s death. So the team could turn off the PGE2 signal while the cancer cells still died. They did this two ways: by stopping the cells from making PGE2, and by blocking the PGE2 signal. Either way, the scouts started working again, the fighters responded, and the tumors were eliminated effectively.

In plain terms, the cancer cells were sending out a “stand down” order, and the scientists found how to cancel it.

Why does this matter?

Some cancers resist the treatments we have today. Ferroptosis is a promising way to attack them, but the tumor’s hiding trick has held it back. Now that the trick is known, researchers have a clear target. The authors say their findings could be used for cancer therapy.

What you can do today

There is nothing new to do yet. This finding is still in the lab, so it does not change current advice, and no treatment based on it is available. If you or someone you love is in cancer care, keep following the plan you have with your care team. Good research like this is how better options get built over time.

For clinicians and researchers

Design: Preclinical study in mouse cancer models and cancer cells examining ferroptosis-inducing strategies, dendritic cells (cDC1s) and CD8+ T cell responses. Sample size and follow-up are not given in the abstract.

Main result: Ferroptotic cancer cells produced prostaglandin E2 (PGE2) via Ca2+ influx and p38 MAPK signalling, which limited cDC1-mediated CD8+ T cell responses. Ablating PGE2 production or signalling restored these responses and led to effective tumour elimination.

Main limitation: Preclinical work in mouse models and cell systems; findings may not translate to patients, and the abstract reports no effect sizes or sample sizes.

How it fits: Extends the earlier early-trial report on an immunotherapy drug shrinking resistant tumours by describing a distinct, preclinical mechanism of tumour immune escape. Early trial: a new immunotherapy drug shrank some tumors that usually resist it

Open question: Whether targeting the p38 MAPK-PGE2 axis alongside ferroptosis induction preserves cancer cell killing and restores antitumour immunity in human patients remains to be tested.

Talk about it at home

Your body has a team of scouts and fighters. The scouts spot something that does not belong and show the fighters what to go after. Scientists found that some unhealthy cells in the lab send a sneaky message, a bit like a do not disturb sign hung on a doorknob, that tells the scouts to stand down, and they also found a way to take the sign down so the team could get back to work.

Try it at home

Ask a grandparent or an older neighbor how news and messages traveled when they were young, before phones were in every pocket, and what happened when a message got lost on the way.

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Lab study finds dying cancer cells switch off the immune attack, a clue for immunotherapy. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/how-tumors-hide-from-immunotherapy-lab-study/
Vancouver
Mongevity Desk. Lab study finds dying cancer cells switch off the immune attack, a clue for immunotherapy [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/how-tumors-hide-from-immunotherapy-lab-study/
APA
Mongevity Desk. (2026, November 22). Lab study finds dying cancer cells switch off the immune attack, a clue for immunotherapy. Mongevity. https://mongevity.science/cancer/2026/11/how-tumors-hide-from-immunotherapy-lab-study/
For your website
<a href="https://mongevity.science/cancer/2026/11/how-tumors-hide-from-immunotherapy-lab-study/">Lab study finds dying cancer cells switch off the immune attack, a clue for immunotherapy</a>

Free to share or quote with credit and a link.

Questions and answers

Is there a new cancer treatment I can get from this?
Not yet. This was lab research, and it has not been tested in people. It does not change current advice.
What is PGE2?
It is a chemical signal. In this study, dying cancer cells made it, and it weakened the immune cells that start the attack on the tumor.
What is ferroptosis?
It is a way a cell dies when the fatty wall around it is damaged by a kind of chemical rust. Many cancers are weak to it.
What did blocking the signal do?
It brought the immune attack back. The cancer cells still died, and the tumors were eliminated effectively.

Sources

  1. Nature: Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape (PMID 43052444 · DOI 10.1038/s41586-026-11333-6) · 2026-11-22

More on this story

Report an error